, Columnist
Who’s Really Keeping Ozempic and Wegovy Prices So High?
The steep cost of obesity drugs is a barrier for patients and a risk to the US health insurance system.
Footing the bill.
Photographer: Al Drago/BloombergThis article is for subscribers only.
On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen over the high price of the company’s diabetes and obesity drugs, Ozempic and Wegovy. Now the question is whether those prices will change.
Vermont Senator Bernie Sanders, chair of the Senate health committee, focused his sights not only on Novo Nordisk, but on the broader forces that drive up US health care costs. Even so, it’s hard to imagine any quick way to improve access and affordability for these drugs.